| ZEVRA THERAPEUTICS |
| USA |
| Gesundheit |
| US4884452065 / A2QLX7 |
| 1GDA (Frankfurt) / ZVRA (NASDAQ) |
| FRA:1GDA, ETR:1GDA, 1GDA:GR, NASDAQ:ZVRA |
| - |
| https://zevra.com/ |
|
Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on rare diseases. Its current business centers on developing and commercializing therapies for patients with serious conditions that have limited or no treatment options..
>Volltext.. |
| 639.42 Mio. EUR |
| 466.82 Mio. EUR |
| 133.21 Mio. EUR |
| 43.15 Mio. EUR |
| 67.58 Mio. EUR |
| 1.16 EUR |
| 1.11 Mio. EUR |
| 110.11 Mio. EUR |
| 34.92 Mio. EUR |
| 4.73 |
| 81.38% |
| 119.82% |
| - |
| - |
| - |
| - |
| ZEVRA |
| 13.11.26 |
|
||||
|
||||
|